• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Transl Med . The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome

tetano

Editor, Senior Moderator
J Transl Med


. 2020 Dec 3;18(1):457.
doi: 10.1186/s12967-020-02646-9.
The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome


Mathieu Blot[SUP] 1 2 [/SUP], Jean-Baptiste Bour[SUP] 3 [/SUP], Jean Pierre Quenot[SUP] 4 5 6 7 [/SUP], Abderrahmane Bourredjem[SUP] 6 7 [/SUP], Maxime Nguyen[SUP] 4 8 [/SUP], Julien Guy[SUP] 9 [/SUP], Serge Monier[SUP] 4 10 [/SUP], Marjolaine Georges[SUP] 11 [/SUP], Audrey Large[SUP] 5 [/SUP], Auguste Dargent[SUP] 4 5 [/SUP], Alexandre Guilhem[SUP] 12 [/SUP], Suzanne Mouries-Martin[SUP] 13 [/SUP], Jeremy Barben[SUP] 14 [/SUP], Belaid Bouhemad[SUP] 4 8 [/SUP], Pierre-Emmanuel Charles[SUP] 4 5 [/SUP], Pascal Chavanet[SUP] 15 6 7 [/SUP], Christine Binquet[SUP] 4 6 7 [/SUP], Lionel Piroth[SUP] 15 6 7 [/SUP], LYMPHONIE study group



Affiliations

Abstract

Background: Although immune modulation is a promising therapeutic avenue in coronavirus disease 2019 (COVID-19), the most relevant targets remain to be found. COVID-19 has peculiar characteristics and outcomes, suggesting a unique immunopathogenesis.
Methods: Thirty-six immunocompetent non-COVID-19 and 27 COVID-19 patients with severe pneumonia were prospectively enrolled in a single center, most requiring intensive care. Clinical and biological characteristics (including T cell phenotype and function and plasma concentrations of 30 cytokines) and outcomes were compared.
Results: At similar baseline respiratory severity, COVID-19 patients required mechanical ventilation for significantly longer than non-COVID-19 patients (15 [7-22] vs. 4 (0-15) days; p = 0.0049). COVID-19 patients had lower levels of most classical inflammatory cytokines (G-CSF, CCL20, IL-1β, IL-2, IL-6, IL-8, IL-15, TNF-α, TGF-β), but higher plasma concentrations of CXCL10, GM-CSF and CCL5, compared to non-COVID-19 patients. COVID-19 patients displayed similar T-cell exhaustion to non-COVID-19 patients, but with a more unbalanced inflammatory/anti-inflammatory cytokine response (IL-6/IL-10 and TNF-α/IL-10 ratios). Principal component analysis identified two main patterns, with a clear distinction between non-COVID-19 and COVID-19 patients. Multivariate regression analysis confirmed that GM-CSF, CXCL10 and IL-10 levels were independently associated with the duration of mechanical ventilation.
Conclusion: We identified a unique cytokine response, with higher plasma GM-CSF and CXCL10 in COVID-19 patients that were independently associated with the longer duration of mechanical ventilation. These cytokines could represent the dysregulated immune response in severe COVID-19, as well as promising therapeutic targets. ClinicalTrials.gov: NCT03505281.

Keywords: Acute respiratory distress syndrome; COVID-19; CXCL10; GM-CSF; Immune response; Mechanical ventilation; Pneumonia.
 
Back
Top Bottom